FREMONT, Calif., July 10, 2025 — Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in four areas: breast, lung and colorectal cancers, and solid tumor immunotherapy monitoring. The addition of CRC follows the presentation of compelling interim analysis results from the VICTORI study at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which demonstrated strong performance of NeXT Personal for detecting early signs of residual or recurrent CRC.
Colorectal cancer affects over 150,000 new patients in the U.S. annually, with many patients experiencing recurrence after initial treatment.
Personalis has amended its agreement with Tempus to further accelerate the adoption of NeXT Personal. The updated terms will:
Expand the collaboration by adding CRC as the fourth indication for which Tempus will serve as Personalis’ exclusive commercial partner
Extend the term of the initial agreement to November 2029
Lengthen the period of Tempus’ exclusivity for all four indications through 2028
“This deepened collaboration is a key component of our ‘Win in MRD’ strategy,” said Chris Hall, CEO of Personalis. “Every day, thousands of cancer survivors live with the uncertainty of whether their cancer will return. By expanding our collaboration with Tempus to include CRC, we’re bringing peace of mind to more patients while building the evidence needed for broad reimbursement coverage for multiple indications.”
By combining Personalis’ highly sensitive MRD testing platform with Tempus’ extensive market reach, the collaboration aims to equip oncologists with a powerful new tool to detect cancer recurrence earlier and manage their patients with a more personalized approach.
“The clinical performance we’re seeing across cancer types demonstrates that ultra-sensitive detection fundamentally changes how we can monitor cancer patients,” Hall added. “With Tempus’ reach to over 50% of U.S. oncologists, we’re accelerating access to technology that gives both physicians and patients the information they need when it matters most.”